Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251095 | 0.88 | AURKA (0.45) | BCL6AURKAGAAMEN1KMT2A | |
| SCHEMBL3245349 | 0.84 | APP (0.50) | AURKAGAAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3254112 | 0.83 | APP (0.49) | AURKAGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3253485 | 0.79 | EGFR (0.53) | AURKAGAAMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3253518 | 0.78 | EGFR (0.52) | GAAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL7006376 | 0.78 | MERTK (0.38) | BCL6GAAMAPTPOLBADORA1 | |
| SCHEMBL3251723 | 0.75 | KDM4E (0.45) | BCL6GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL3251731 | 0.75 | AURKA (0.45) | BCL6AURKAGAAMEN1KMT2A | |
| SCHEMBL6642666 | 0.74 | PIN1 (0.51) | BCL6AURKAMEN1KMT2AMAPT | |
| SCHEMBL6474471 | 0.73 | BCL6 (0.49) | BCL6AURKAGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | claimed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | claimed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-0989460-B1 | PATTERN FORMING METHOD | AZ ELECTRONIC MATERIALS USA (US) | 2010-05-26 | — | — | EP | disclosed |
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | disclosed |
| US-6527966-B1 | Forming a pattern composed of an etchable layer by conducting dry etching of an etchable layer formed on a substrate for semiconductor through a mask of patterned radiation sensitive material coating formed on the etchable layer | CLARIANT FINANCE (BVI) LIMITED (VG) | 2003-03-04 | — | — | US | disclosed |
| EP-0989460-A1 | PATTERN FORMING METHOD | Clariant Finance (BVI) Limited (VG) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | BDNF, NTRK2, GAP43 | BCL6 3385/4885AURKA 3580/4885GAA 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.